Cytori to Webcast Cardiac Cell Therapy Teach-In Tuesday Nov. 16 From the American Heart Association

San Diego, (PresseBox) - Cytori Therapeutics (NASDAQ: CYTX) will be hosting an investor teach-in on cardiac cell therapy on Tuesday, November 16 from 7:00-8:00 AM CT (8:00-9:00 AM ET) from the American Heart Association meeting in Chicago. The goal is to help investors evaluate the several ongoing clinical trials and approaches to using stem cells for the treatment of heart attacks, heart failure and other vascular diseases. The presentation will be webcast live and can be accessed from the Investor Relations section of Cytori's website at

Investigators from Cytori's APOLLO and PRECISE studies will review their clinical trial experience, the attributes of various sources for stem cells, and how, when and where cells should be delivered. In addition, they will each discuss future directions for the field, including trial design, endpoints, ways to further enhance the effects of the cells, and how such therapies will integrate with current standard-of-care. A Q&A session will be led and moderated by Jan Wald, PhD, of Noble Financial.

Cytori Therapeutics, Inc.

Cytori is a leader in providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource® product line is sold globally for cell banking and research applications.

Diese Pressemitteilungen könnten Sie auch interessieren

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.

Ich möchte die kostenlose Pressemail abonnieren und habe die Bedingungen hierzu gelesen und akzeptiert.